fashion -WSS

fashion

author：comprehensive 2025-09-30 00:10:15 - browse：8584

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Juul documents reveal insider tactics on political lobbying

knowledge

WSS

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Senators: Long

Abbott's new heart device gets FDA advisory panel nod

STAT Virtual Event: Putting AI to the Test

STAT Boddities: What happens to the brain when we get scared?

Tome Biosciences co

leisure time

fashion

focus

New air purifier tech could be key to improving indoor air quality

Senators: Long

At least 13 dead in Texas as scorching temps continue

Ukraine and a new approach to mental health in war

DIEP, the 'gold standard' of breast reconstruction, is under threat

Intarcia’s device

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What Congress can do to address the rural doctor shortage

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

Emergency workers more likely to restrain Black patients: study

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Juul documents reveal insider tactics on political lobbying

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

How AI helped researchers track recovery from depression

hotspot

knowledge

focus

leisure time